Introduction
Tofacitinib, an oral Janus kinase (JAK) inhibitor, has been increasingly
over-scheduled for the treatment of rheumatologic disorders,
particularly for challenging rheumatologic conditions that exhibit
resistance to conventional treatment regimens.1-2Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is
a rare autoinflammatory disease characterized by osteoarticular and
dermatological manifestations, for which there is a lack of standardized
treatment. Notably, tofacitinib has demonstrated substantial
multidimensional improvements in pain, skin lesions, systemic
inflammation, quality of life, and magnetic resonance imaging remission
in patients with SAPHO syndrome. Consequently, it is increasingly being
employed in refractory SAPHO syndrome cases where biologic therapy has
proven ineffective.3-4 However, limited data exist
regarding its use during human pregnancies. Here, we report a case of an
unintended pregnancy in a patient with SAPHO syndrome who was treated
with tofacitinib.